High free fatty acid concentration: An independent risk factor for hypertension in the Paris Prospective Study

International Journal of Epidemiology

Volumn 27, Issue 5, 1998, Pages 808-813

  Fagot Campagna, Anne ^a,e   Balkau, Beverley ^a   Simon, Dominique ^a,b   Warnet, Jean Michel ^c   Claude, Jean Roger ^c   Ducimetière, Pierre ^d   Eschwège, Eveline ^a  

^a UNIVERSITÉ PARIS SACLAY   (France)

^b HENRI MONDOR HOSPITAL   (France)

^c UNIVERSITÉ PARIS DESCARTES   (France)

^d HÔPITAL BROUSSAIS   (France)

^e NATIONAL CENTER FOR CHRONIC DISEASE PREVENTION AND HEALTH PROMOTION   (United States)

Author keywords

Essential hypertension; Free fatty acids; Insulin; Lipids; Men; Obesity

Indexed keywords

FATTY ACID; INSULIN;

ADULT; ALCOHOL CONSUMPTION; ARTICLE; BODY MASS; BODY WEIGHT; CAUCASIAN; DIASTOLIC BLOOD PRESSURE; FAMILY HISTORY; FATTY ACID BLOOD LEVEL; HEART RATE; HUMAN; HYPERTENSION; INCIDENCE; INSULIN RESISTANCE; MALE; NORMAL HUMAN; PRIORITY JOURNAL; PROSPECTIVE STUDY; RISK FACTOR; SYSTOLIC BLOOD PRESSURE;

ADULT; CONFOUNDING FACTORS (EPIDEMIOLOGY); FATTY ACIDS, NONESTERIFIED; HUMANS; HYPERTENSION; MALE; MIDDLE AGED; PARIS; PROSPECTIVE STUDIES; RISK FACTORS;

EID: 0031731386     PISSN: 03005771     EISSN: None     Source Type: Journal    
DOI: 10.1093/ije/27.5.808     Document Type: Article

References (62)

1. Reaven GM. Role of insulin resistance in human disease. Diabetes 1988;37:1595-606.
2. Ferrannini E, Haffner SM, Mitchell BD, Stern MR Hyperinsulinemia: the key feature of a cardiovascular and metabolic syndrome. Diabetologia 1991;34:416-22.
3. Björntorp P. Fatty acids, hyperinsulinemia, and insulin resistance: which comes first? Curr Opin Lipidol 1994;5:166-74.
4. Reaven GM. The Fourth Musketeer - from Alexandre Dumas to Claude Bernard. Diabetologia 1995;38:3-13.
5. Randle PJ, Garland PB, Hales CN, Newsholme EA. The glucose fattyacid cycle. Its role in insulin sensitivity and the metabolic disturbances of diabetes mellitus. Lancet 1963;13:785-89.
6. Groop LC, Ferrannini E. Insulin action and substrate competition. Bailiieres Clin Endocrinol Metab 1993;7:1007-32.
7. Saloranta C, Koivisto V, Widen E et al. Contribution of muscle and liver to glucose-fatty acid cycle in humans. Am J Physiol 1993;264: E599-605.
8. Nuutila P, Koivisto VA, Knuuti J et al. Glucose-free fatty acid cycle operates in human heart and skeletal muscle In vivo. J Clin Invest 1992;89:1767-74.
9. Unger RH. Lipotoxicity in the pathogenesis of obesity-dependent NIDDM. Genetic and clinical implications. Diabetes 1995;44:863-70.
10. Paolisso G, Tataranni PA, Foley JE, Bogardus C, Howaid BV, Ravussin E, A high concentration of fasting plasma non-esterified fatty acids is a risk factor for the development of NIDDM. Diabetologia 1995;38: 1213-17.
11. Charles MA, Eschwège E, Thibult N et al. The role of non-esterified fatty acids in the deterioration of glucose tolerance in Caucasian subjects: results of the Paris Prospective Study. Diabetologia 1997;40: 1101-06.
12. Niskanen LK, Uusitupa MI, Pyörälä K. The relationship of hyperinsuiinemia to the development of hypertension in type 2 diabetic patients and in non-diabetic subjects. J Hum Hypertens 1991;5:155-59.
13. Flack JM, Liu K, Savage P et al. Baseline insulin predicts 2 year blood pressure change in young adults: the CARDIA study. Circulation 1991;83:724 (abstract).
14. Vaccaro O, Imperatore G, lovino V, Iovine C, Rivellese AA, Riccardi G. Does impaired glucose tolerance predict hypertension? A prospective analysis. Diabetologia 1996;39:70-76.
15. Shetterly SM, Rewers M, Hamman RF, Marshall JA. Patterns and predictors of hypertension incidence among Hispanics and nonHispanic Whites: The San Luis Valley Diabetes Study. J Hypertension 1994;12:1095-102.
16. Lissner L, Bengtsson C, Lapidus L, Kristjansson K, Wedel H. Fasting insulin in relation to subsequent blood pressure changes and hypertension in women. Hypertension 1992;20:797-801.
17. Stern MP, Morales PH, Haffner SM, Valdez RA. Hyperdynamic circulation and the insulin resistance syndrome ('Syndrome X'). Hypertension 1992;20:802-08.
18. Hafmer SM, Valdez RA, Hazuda HP, Mitchell BD, Morales PA, Stern MP. Prospective analysis of the insulin-resistance syndrome (syndrome X). Diabetes 1992;41:715-22.
19. Skarfors ET, Lithell HO, Selinus I. Risk factors for the development of hypertension: a 10-year longitudinal study in middle-aged men. J Hypertension 1991;9:217-23.
20. Fagot-Campagna A, Balkau B, Simon D, Ducimetière P, Eschwège E. Is insulin an independent risk factor for hypertension? The Paris Prospective Study. Int J Epidemiol 1997;26:542-50.
21. Methodology Technicon Auto-Analyzer N 2a, 2nd Edn. Tarrytown NY: Technicon Ltd., 1963.
22. Rosselin GE, Assan R, Yalow RS, Berson SA. Separation of antibody bound and unbound peptide hormone labelled with iodine 131 by talcum powder and precipitated silica. Nature 1966;212:355-57.
23. Antonis A. Semi-automated method for the colorimetric determination of plasma free fatty acid. J Lipid Res 1965;6:307-12.
24. Etienne G, Papin J, Renault H. Une méthode simple de dosage du cholestérol total par voie automatique. Ann Biol Clin 1963;21:851-59.
25. Claude JR, Corre F. Considérations pratiques sur le dosage semiautomatique des triglycérides sériques par fluorométrie (méthode de Kessler et Lederer). Comparaison avec la méthode manuelle colorimétrique de Van Handel et Zilversmit. Ann Biol Clin 1968; 26:451-54.
26. WHO Expert Committee. Arterial hypertension. World Health Organ Tech, Tech Rep Ser 1978; No 628.
27. Chick J, Kreitman N, Plant M. Mean cell volume and gammaglutamyl-transpeptidase as markers of drinking in working men. Lancet 1981;i:1249-51.
28. Cox DR. Regression models and life-tables (with discussion). J R Statist Soc B 1971;34:187-220.
29. Shaper AG, Wannamethee G, Macfarlane PW, Walker M. Heart rate, ischaemic heart disease, and sudden cardiac death in middle-aged British men. Br Heart J 1993;70:49-55.
30. Breslow NE, Day NE. Statistical Methods in Cancer Research. Vol. I The Analysis of Case-Control Studies. Lyon: International Agency for Research on Cancer. Publication No. 32, 1980, pp.191-259.
31. Kalbfleisch JD, Prentice RL. The Statistical Analysis of Failure Time Data. New York: John Wiley & Sons, 1980, pp.119-42.
32. Stepniakowski KT, Egan BM. Additive effects of obesity and hypertension to limit venous volume. Am J Physiol 1995;37:R562-68.
33. Stepniakowski KT, Goodfriend TL, Egan BM. Fatty acids enhance vascular a-adrenergic sensitivity. Hypertension 1995; 25[part2]:774-78.
34. Egan BM, Hennes MMI, Stepniakowski KT, O'Shaughnessy IM, Kissebah AH, Goodfriend TL. Obesity hypertension is related more to insulin's fatty acid than glucose action. Hypertension 1996;27[part2]:723-28.
35. Hennes MMI, O'Shaughnessy IM, Kelly TM, LaBelle P, Egan BM, Kissebah AH. Insulin-resistant lipolysis in abdominally obese hypertensive individuals. Role of the renin-angiotensin system. Hypertension 1996;28:120-26.
36. Swislocki A, Eason T. Glucose tolerance and blood pressure are improved in the spontaneously hypertensive rat by ethyl-2-(6(4-chlorophenoxy)-hexyl)oxirane-2-carboxyIate (etomoxir), an inhibitor of fatty acid oxidation. Am J Hypertens 1994;7:739-44.
37. Billow J, Madsen J, Astrup A, Christensen NJ. Vasoconstrictor effect of high FFA/albumin ratios in adipose tissue in vivo. Acta Physiol Scand 1985;125:661-67.
38. Bülow J, Madsen J, Hojgaard L. Reversibility of the effects on local circulation of high lipid concentrations in blood. Scand J Clin Lab Invest 1990;50:291-96.
39. Grekin RJ, Vollmer AP, Sider RS. Pressor effects of portal venous oleate infusion. A proposed mechanism for obesity hypertension. Hypertension 1995;26:193-98.
40. Vesell ES, Chambers CE, Passananti GT, Demers LM, Beyer KH. Effects of pyrazinoyiguanidine on the glucose-fatty acid cycle in normal subjects and patients with non-msulin-dependent diabetes mellitus. J Clin Pharmacol 1993;33:823-31.
41. Chambers CE, Vesell ES, Helm C, Passananti GT, Beyer KH. Pyrazinoyiguanidine: antihypertensive, hypocholesterolemic, and fenin effects. J Clin Pharmacol 1992;32:1128-34.
42. Egan BM, Stepniakowski KT. Evidence linking fatty acids, the risk factor duster, and vascular pathophysiology: Implications for the diabetic hypertensive patient. In: Sowers JR (ed.). Contemporary Endocrinology: Endocrinology of the Vasculature. Totowa MJ: Humana Press Inc.,1996, pp. 157-72.
43. Ordway RW, Singer JJ, Walsh JV. Direct regulation of ion channels by fatty acids. Trends Neurosci 1991;14:96-100.
44. Ng LL, Hockaday TDK. Non-esterified fatty acids may regulate human leucocyte sodium pump activity. Clin Sci 1986;71:737-42.
45. Kelly RA, O'Hara DS, Mitch WE, Smith TW. Identification of NaKATPase inhibitors in human plasma as nonesterified fatty acids and lysophospholipids. J Biol Chem 1985;260:11396-405.
46. Goodfriend TL, Ball DL, Elliott ME, Morrison AR, Evenson MA. Fatty acids are potential endogenous regulators of aldosterone secretion. Endocrinology 1991;128:2511-19.
47. Davda RK, Stepniakowski KT, Lu G, Ullian ME, Goodfriend TL, Egan BM. Oleic acid inhibits endothelial nitric oxide synthase by a protein kinase C-independent mechanism. Hypertension 1995;26:764-70.
48. FoIey JE. Rationale and application of fatty acid oxidation inhibitors in treatment of diabetes mellitus. Diabetes Care 1992;15:773-84.
49. Monti LD, Lucignani G, Landoni C et al. Myocardial glucose uptake evaluated by positron emission tomography and fluorodeoxyglucose during hyperglycemie damp in IDDM patients. Role of free fatty acid and insulin levels. Diabetes 1995;44:537-42.
50. Ship JC, Opie LH, Challoner D. Fatty acid and glucose metabolism in the perfused heart. Nature 1961;189:1018-19.
51. Bressler R, Gay R, Copeland JG, Bahl JJ, Bedotto J, Goldman S. Chronic inhibition of fatty acid oxidation: new model of diastolic dysfunction. Life Sci 1989;44:1897-906.
52. Burges RA, Gardiner DG, Higgins AJ. Protection of the ischaemic dog heart by oxfenicine. Life Sci 1981;29:1847-53.
53. Frayn KT, Williams CM, Arner P. Are increased plasma non-esterified fatty acid concentrations a risk marker for coronary heart diseases and other chronic diseases? Clin Sci 1996;90:243-53.
54. Filipovsky J, Ducimetière P, Eschwège E, Richard JL, Rosselin G, Claude JR. The relationship of blood pressure with glucose, insulin, heart rate, free fatty acids and plasma cortisol levels according to degree of obesity in middle-aged men. J Hypertens 1996;14:229-35.
55. Khan A, Jinagouda S, Damani S et al. Free fatty acids and the insulin resistance syndrome. Diabetologia 1996;39(Suppl.l):A53 (Abstract).
56. Campbell PJ, Carlson GM, Hill OJ, Nurjhan N. Regulation of free fatty acid metabolism by insulin in humans: role of lipolysis and reesterification. Am J Physiol 1992;263:E1063-69.
57. Randrianjohany A, Balkau B, Cubeau J, Ducimetière P, Warnet JM, Eschwège E. The relationship between behavioural pattern, overall and central adiposity in a population of healthy French men. Int J Obes 1993;17:651-55.
58. Kaplan NM. Alcohol and hypertension. Lancet 1995;345:1588-89.
59. Savolainen MJ, Kesäniemi YA. Effects of alcohol on lipoproteins in relation to coronary heart disease. Curr Upin Lipidol 1995;6:243-50.
60. Srivastava LM, Vasisht S, Agarwal DP, Goedde HW. Relation between alcohol intake, lipoproteins and coronary heart disease: The interest continues, Alcohol, Alcohol 1994;29:11-24.
61. Wilking SB, Belanger A, Kannel WB, D'Agostino RB, Steel K. Deter- minants of isolated hypertension. JAMA 1988;23:3451-55.
62. Balkau B, Eschwege E, Papoz L et al. Risk factors for early death in non-insulin dependent diabetes and men with known glucose tolerance status. Br Med J 1993;307:295-99.